256 JIS scoring system combined with 3 tumor makers (modified JIS score) is an exellent prognostic staging system for hepatocellular carcinoma (HCC): Analysis of 4525 patients with HCC
Masatoshi Kudo(Kindai University), Toshihito Seki(Kansai Medical University), Hiroshi Kasugai(Osaka International Cancer Institute), Yukio Osaki(Osaka Red Cross Hospital), Hiroko Oka(Osaka City General Hospital), Yo Sasaki(SHOWA Medical University), Hobyung Chung(Kindai University)
Cited by 20
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Increased Nuclear NAD Biosynthesis and SIRT1 Activation Prevent Axonal Degeneration
|Science|2004|1.1k